Skip to content
2000
Volume 12, Issue 1
  • ISSN: 2215-0838
  • E-ISSN: 2215-0846

Abstract

Background

Psoriasis is a chronic skin disease characterized by erythema, scaling, and thickening. Yinxieling is a representative prescription for treating psoriasis developed by Professor Guowei Xuan, a master of traditional Chinese medicine. Keratin 17 is a key biomarker for the diagnosis and treatment of psoriasis, and its overexpression has been shown to impair mitochondrial function.

Objectives

This study investigates the mechanism of action of Yinxieling in the treatment of psoriasis.

Methods

, BALB/c mice were induced by imiquimod to create psoriasis-like mice model. Different doses of Yinxieling were administered to the psoriasis-like mice and PASI scores, thickness of epidermis and Keratin 17 expression of psoriasis-like mice were measured. , HaCaT cells were induced by IL-17A, IL-22 and TNF-alpha to establish psoriasis-like cells model. Yinxieling with different concentrations was administered to the psoriasis-like cells and Keratin 17 expression, adenosine triphosphate levels, and oxygen consumption rates were measured. Furthermore, the psoriasis-like cells were transfected with keratin 17 plasmids. Yinxieling intervened in these psoriasis-like cells with continuous high expression of keratin 17 and adenosine triphosphate levels and oxygen consumption rates were measured.

Results

Yinxieling significantly improved PASI scores and decreased their epidermal thickness in psoriasis-like mice; Yinxieling also inhibited Krt17 expression in psoriasis-like mice and cells. Yinxieling improved ATP levels and oxygen consumption rate in psoriasis-like cells, and this effect of Yinxieling was abolished when the psoriasis-like cells were transfected with keratin 17 plasmids.

Discussion

These findings suggest that Yinxieling alleviates psoriatic inflammation and improves mitochondrial function by downregulating KRT17. The study provides new mechanistic insights into the traditional use of Yinxieling and underscores the link between keratin dysregulation and mitochondrial impairment in psoriatic pathology.

Conclusion

Yinxieling inhibits keratin 17 to enhance mitochondrial function and ameliorates psoriasis-like lesions.

This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/ctm/10.2174/0122150838312001241002094020
2024-10-23
2025-11-12
Loading full text...

Full text loading...

/deliver/fulltext/ctm/12/1/CTM-12-E22150838312001.html?itemId=/content/journals/ctm/10.2174/0122150838312001241002094020&mimeType=html&fmt=ahah

References

  1. BonnekohB BockelmannR. Keratin 17/interferon-gamma autoimmune loop as a vicious circle driving psoriasis pathogenesis.J. Am. Acad. Dermatol.200756116210.1016/j.jaad.2006.07.03417190635
    [Google Scholar]
  2. LiuW. JiangJ. LiZ. XiaoY. ZhouS. WangD. ZouY. LiuT. LiK. LiangH. WangN. XiangX. XieQ. ZhanR. ZhangJ. ZhouX. YangL. ChuongC.M. LeiM. Energy competition remodels the metabolic glucose landscape of psoriatic epidermal cells.Theranostics20241483339335710.7150/thno.9376438855186
    [Google Scholar]
  3. ShiX. JinL. DangE. ChangT. FengZ. LiuY. WangG. IL-17A upregulates keratin 17 expression in keratinocytes through STAT1- and STAT3-dependent mechanisms.J. Invest. Dermatol.2011131122401240810.1038/jid.2011.22221796151
    [Google Scholar]
  4. ZhangJ. LiX. WeiJ. ChenH. LuY. LiL. HanL. LuC. Gallic acid inhibits the expression of keratin 16 and keratin 17 through Nrf2 in psoriasis-like skin disease.Int. Immunopharmacol.201865849510.1016/j.intimp.2018.09.04830293051
    [Google Scholar]
  5. FuM. WangG. Keratin 17 as a therapeutic target for the treatment of psoriasis.J. Dermatol. Sci.201267316116510.1016/j.jdermsci.2012.06.00822795618
    [Google Scholar]
  6. KumarV. BouameurJE. BärJ. A keratin scaffold regulates epidermal barrier formation, mitochondrial lipid composition, and activity.J. Cell Biol.201521151057107510.1083/jcb.20140414726644517
    [Google Scholar]
  7. ZhangJ. YangX. QiuH. ChenW. Weight loss may be unrelated to dietary intake in the imiquimod-induced plaque psoriasis mice model.Open Life Sci.2020151798210.1515/biol‑2020‑0009
    [Google Scholar]
  8. ZhangJ. QiuH. CaoX. HanL. The anti-psoriatic effect of gallic acid is associated with the suppression of keratin 6 and Nrf2.Lett. Drug Des. Discov.20242191532154510.2174/1570180820666230314103222
    [Google Scholar]
  9. Global report on psoriasis.2016Available from: https://www.who.int/publications/i/item/9789241565189
  10. YangL. FanX. CuiT. DangE. WangG. Nrf2 promotes keratinocyte proliferation in psoriasis through up-regulation of keratin 6, keratin 16, and keratin 17.J. Invest. Dermatol.2017137102168217610.1016/j.jid.2017.05.01528576737
    [Google Scholar]
  11. ChangT. SunL. WangY. WangD. LiW. LiC. GaoT. LiuY. WangG. Inhibition of keratin 17 expression with antisense and RNAi strategies: Exploring novel therapy for psoriasis.Exp. Dermatol.201120755556010.1111/j.1600‑0625.2010.01235.x21355890
    [Google Scholar]
  12. JinL. WangG. Keratin 17: A critical player in the pathogenesis of psoriasis.Med. Res. Rev.201434243845410.1002/med.2129123722817
    [Google Scholar]
  13. WangX. NiuL. KangA. Effects of ambient PM2.5 on development of psoriasiform inflammation through KRT17-dependent activation of AKT/mTOR/HIF-1α pathway.Ecotoxicol. Environ. Saf.202224311400810.1016/j.ecoenv.2022.11400836029575
    [Google Scholar]
  14. CserniD. ZomboriT. VörösA. A Clinicopathological approach to odontogenic cysts: The role of cytokeratin 17 and bcl2 immunohistochemistry in identifying odontogenic keratocysts.Pathol. Oncol. Res.2642613262010.1007/s12253‑020‑00866‑432632899
    [Google Scholar]
  15. YueZ. LinJ. LuX. Keratin 17 impacts global gene expression and controls g2/m cell cycle transition in ionizing radiation-induced skin damage.J. Invest. Dermatol.20231431224362446.e1310.1016/j.jid.2023.02.04337414246
    [Google Scholar]
  16. CassinaL. ChiaravalliM. BolettaA. Increased mitochondrial fragmentation in polycystic kidney disease acts as a modifier of disease progression.FASEB J.20203456493650710.1096/fj.201901739RR32239723
    [Google Scholar]
  17. GrubelnikV. MarkovičR. LipovšekS. Modelling of dysregulated glucagon secretion in type 2 diabetes by considering mitochondrial alterations in pancreatic α-cells.R. Soc. Open Sci.20207119117110.1098/rsos.19117132218947
    [Google Scholar]
  18. HanY. ChuX. CuiL. Neuronal mitochondria-targeted therapy for Alzheimer's disease by systemic delivery of resveratrol using dual-modified novel biomimetic nanosystems.Drug Deliv.202027150251810.1080/10717544.2020.1745328
    [Google Scholar]
  19. KePY. Mitophagy in the pathogenesis of liver diseases.Cells20209483110.3390/cells904083132235615
    [Google Scholar]
  20. Li PumaL.C. HedgesM. HeckmanJ.M. MathiasA.B. EngstromM.R. BrownA.B. ChiccoA.J. Experimental oxygen concentration influences rates of mitochondrial hydrogen peroxide release from cardiac and skeletal muscle preparations.Am. J. Physiol. Regul. Integr. Comp. Physiol.20203185R972R98010.1152/ajpregu.00227.201932233925
    [Google Scholar]
  21. NödlingA.R. MillsE.M. LiX. CardellaD. SayersE.J. WuS.H. JonesA.T. LukL.Y.P. TsaiY.H. Cyanine dye mediated mitochondrial targeting enhances the anti-cancer activity of small-molecule cargoes.Chem. Commun. (Camb.)202056344672467510.1039/C9CC07931A32211623
    [Google Scholar]
  22. SuS. NdiayeM. SinghCK. AhmadN. Mitochondrial sirtuins in skin and skin cancers.Photochem. Photobiol.202096597398010.1111/php.1325432124989
    [Google Scholar]
/content/journals/ctm/10.2174/0122150838312001241002094020
Loading
/content/journals/ctm/10.2174/0122150838312001241002094020
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test